New catheter may sharpen radiation targeting in liver tumors

NCT ID NCT05128032

First seen Jun 24, 2026 · Last updated Jul 21, 2026 · Updated 5 times

Summary

This study compares two catheters used during the mapping step before radioembolization for liver cancer. One is a standard microcatheter, the other is a pressure-enabled device (TriNav). The goal is to see if the pressure-enabled catheter delivers more radioactive tracer directly to tumors rather than to healthy liver tissue. Twenty adults with liver cancer (hepatocellular carcinoma or colorectal metastases) who are already scheduled for radioembolization will participate.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
TriNav Infusion System (pressure-enabled drug delivery catheter)
What this could lead to
If successful, this could show that a special catheter delivers radiation more precisely to liver tumors, potentially improving future radioembolization treatments.
What could go wrong
This is a small, early-phase study with only 20 participants, so results may not apply to all patients. It measures imaging outcomes, not actual treatment success or survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts, 02245, United States

  • Massachusetts General Hospital Cancer Center

    Boston, Massachusetts, 02114, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.